Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program.
Abstract | OBJECTIVES:: MATERIALS AND METHODS::
Nivolumab (3 mg/kg every 2 weeks for ≤24 months) was available on physician request. Efficacy data included objective tumor response, date of progression, and survival information. Safety was monitored. RESULTS:: Overall, 371 patients received at least one dose of nivolumab, including 31 never-smokers (8%). Objective response rate, disease-control rate, and median overall survival were 23%, 45%, and 12.1 months (95% confidence interval: 3.7-20.4), respectively, in never-smokers, and 18%, 47%, and 7.9 months (95% confidence interval: 6.2-9.6), respectively, in the overall expanded access program population. Any-grade and grade 3-4 treatment-related adverse events were reported in 12 (39%) and 3 (10%) never-smokers, respectively, and in 109 (29%) and 21 (6%) patients, respectively, in the overall expanded access program population. Grade 3-4 treatment-related adverse events in non-smokers were increased transaminases (n = 2; 6%) and diarrhea (n = 1; 3%). Treatment-related adverse events led to treatment discontinuation in 4 non-smokers (17%) and in 26 patients (9%) overall. CONCLUSION::
|
Authors | Marina Chiara Garassino, Lucio Crinò, Annamaria Catino, Andrea Ardizzoni, Enrico Cortesi, Federico Cappuzzo, Paola Bordi, Luana Calabrò, Fausto Barbieri, Antonio Santo, Giuseppe Altavilla, Francesca Ambrosio, Enrico Mini, Enrico Vasile, Floriana Morgillo, Alessandro Scoppola, Carmelo Bengala, Alessandro Follador, Natale Tedde, Diana Giannarelli, Giuseppe Lo Russo, Fabiana Vitiello |
Journal | Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
(Tumour Biol)
Vol. 40
Issue 11
Pg. 1010428318815047
(Nov 2018)
ISSN: 1423-0380 [Electronic] Netherlands |
PMID | 30486741
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Carcinoma, Non-Small-Cell Lung
(drug therapy, pathology)
- Carcinoma, Squamous Cell
(drug therapy, pathology)
- Case-Control Studies
- Cohort Studies
- Disease Progression
- Female
- Follow-Up Studies
- Health Services Accessibility
- Humans
- Lung Neoplasms
(drug therapy, pathology)
- Male
- Middle Aged
- Nivolumab
(therapeutic use)
- Non-Smokers
(statistics & numerical data)
- Prognosis
- Survival Rate
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|